GlaxoSmithKline Pharmaceuticals Limited

Registered Office: Dr. Annie Besant Road, Mumbai - 400 030 CIN: L24239MH1924PLC001151 Tel No: +91 22 2495 9595 Fax No: +91 22 24959494

STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH, 2023

(Rs. in Lakhs)

	Particulars	3 months ended 31.03.2023 (Unaudited)	3 months ended 31.12.2022 (Unaudited)	Corresponding 3 months ended 31.03.2022 (Unaudited) (Refer Note 2	Year ended 31.03,2023 (Audited)	Year ended 31.03.2022 (Audited)
		(Refer Note 2)		and 6)	(Refer Note 6)	(Refer Note 6)
	Continuing operations			-	· · ·	
	Income					
1	Revenue from operations	78745	80230	80963	325172	327803
2	Other income (Refer Note 3)	2766	2342	1876	10066	7578
3	Total Income (1+2)	81511	82572	82839	335238	335381
	Expenses					
	(a) Cost of materials consumed	9410	4701	14810	42748	61118
	(b) Purchases of stock-in-trade	17779	12462	18410	78843	72944
	(c) Changes in inventories of finished goods, stock-in-			1015		
	trade and work-in-progress	7290	11645	1916	6896	1557
	(d) Employee benefits expense	14884	15299	14004	59499	61023
	(e) Finance costs	65	9	28	181	200
	(f) Depreciation and amortisation expense	1718 12408	1641 13253	1535 14301	6577 56757	6819 54973
4	(g) Other expenses Total expenses	63554	59010	65004	251501	258634
5	Profit before exceptional items and tax (3-4)	17957	23562	17835	83737	76747
6		1040	(1137)		(97)	1158
7	Profit before tax (5+6)	18997	22425	20785	83640	77905
8		20997		20/05	05040	//505
Ŭ	(a) Current tax	5730	6920	5796	24713	21975
	(b) Deferred tax	(76)	(951)	255	(1837)	(941
	(c) Tax adjustment of earlier years (Refer Note 5)	-		20200	-	18794
9		13343	16456	(5466)	60764	38077
	Discontinued operations					
10	[·····································	-	-	165225	413	170818
11		-	-	37854	108	39423
	Profit from discontinued operations after taxes (10-11)	-	-	127371	305	131395
13	Profit for the period (9+12)	13343	16456	121905	61069	169472